Actelion Stops Tezosentan Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The acute heart failure drug has "too remote a chance" of reaching statistically significant efficacy endpoints, an interim analysis by the data safety monitoring board finds. Actelion will wait for a complete analysis of the data before making a further developmental decisions for tezosentan, which would be co-promoted by Genentech.
You may also be interested in...
Actelion Vows To Keep PAH Lead, Despite First-Quarter Dip
Swiss firm blames currency fluctuations and buying patterns for Tracleer and Ventavis sales reductions.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.